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Diazido platinum(IV) complexes for photoactivated
anticancer chemotherapy
Huayun Shi, Cinzia Imberti and Peter J. Sadler *
Diazido Pt(IV) complexes with a general formula [Pt(N3)2(L)(L’)(OR)(OR’)] are a new generation of anti-
cancer prodrugs designed for use in photoactivated chemotherapy. The potencies of these complexes
are aﬀected by the cis/trans geometry conﬁguration, the non-leaving ligand L/L’ and derivatisation of the
axial ligand OR/OR’. Diazido Pt(IV) complexes exhibit high dark stability and promising photocytotoxicity
circumventing cisplatin resistance. Upon irradiation, diazido Pt(IV) complexes release anticancer active Pt
(II) species, azidyl radicals and ROS, which interact with biomolecules and therefore aﬀect the cellular
components and pathways. The conjugation of diazido Pt(IV) complexes with anticancer drugs or cancer-
targeting vectors is an eﬀective strategy to optimise the design of these photoactive prodrugs. Diazido
Pt(IV) complexes represent a series of promising anticancer prodrugs owing to their novel mechanism of
action which diﬀers from that of classical cisplatin and its analogues.
1. Introduction
The treatment of cancer, a group of diseases involving uncon-
trolled growth and spread of cells and representing the leading
cause of death globally, remains a major challenge.1
Phototherapy, consisting of photodynamic therapy (PDT) and
photoactivated chemotherapy (PACT), has attracted much
attention in cancer treatment due to its high spatial-temporal
controllability and minimal invasiveness. The mechanism of
action of clinically approved PDT is based on the combination
of a photosensitiser, light and oxygen.2 High oxygen depen-
dence limits the application of PDT since the oxygen concen-
tration in hypoxic tumours is low. PACT, in contrast to PDT, is
an oxygen-independent phototherapy, which involves chemical
changes of prodrugs upon irradiation and provides a new
avenue in anticancer drug development.3,4
The serendipitous discovery of the antiproliferative pro-
perties of cisplatin in 1968 by Rosenberg et al. stimulated a
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wide research for other platinum-based anticancer drugs.5,6
Platinum drugs are now used to treat over 40% of all cancer
patients in chemotherapy since cisplatin was approved by FDA
in 1978 to treat testicular and ovarian cancers.7–10 Several classes
of platinum anticancer agents, as summarised in Table 1, have
been investigated in the past decades and extensively reviewed
in recent publications.11–21 Compared with Pt(II) complexes,22
Pt(IV) complexes with d6 electronic configuration are more kine-
tically inert to ligand substitution, and more stable under phys-
iological conditions.14,23 Pt(IV) complexes can be reduced by bio-
reductants (e.g. GSH, ascorbic acid, cysteine) to form active Pt(II)
species through which they exert their anticancer activity.24–26
Although some Pt(IV) complexes entered clinical trials, none of
them has been approved for clinical use.27–32
Notably, photodecomposition is a prominent feature of
Pt(IV) complexes, suggesting their potential as PACT
prodrugs.15,33–35 Transition metal azido complexes are usually
light sensitive.36,37 The first photoreductive Pt(IV) complex with
azide ligands reported by Vogler et al. in 1978 was trans-[Pt
(N3)2(CN)4]
2−.38 Upon irradiation with UVA at 302 nm, the
wavelength of its maximum electronic absorbance, assigned as
a ligand-to-metal (N3 → Pt) charge-transfer transition, trans-[Pt
(N3)2(CN)4]
2− was converted to [Pt(CN)4]
2− via the formation of
two azidyl radicals without a Pt(III) intermediate. The unstable
azidyl radicals released nitrogen gas, preventing the re-oxi-
dation of the platinum centre.36 Another azido Pt(IV) complex
[Pt(N3)6]
2− was found to undergo photoreduction, yielding
[Pt(N3)4]
2− and even metallic Pt, accompanied by the release of
nitrogen gas.39,40 These early studies provided a basis for
our group to develop diazido Pt(IV) complexes that are stable
in the dark, and exhibit promising cytotoxicity upon
irradiation.11,15,34,35,41,42
In this review, our discussion begins with a brief introduction
to photoactivated chemotherapy and focuses on the development
of photoactive diazido Pt(IV) complexes, including the design of
new complexes, their photochemistry and photobiology, mecha-
nism of action, derivatisation of axial ligands and conjugation to
nanoparticles to improve photocytotoxicity and selectivity. We
give a comprehensive description of diazido Pt(IV) complexes and
consider feasible strategies for their future clinical use.
2. Photoactivated chemotherapy
PACT relies on light-mediated chemical changes,
transforming an inactive prodrug into an active agent upon
irradiation.3,4,43,44 Platinum-based PACT anticancer drugs can
be activated via diﬀerent mechanisms as described below.
• Photoreduction: Pt(IV) complexes can be reduced upon
irradiation to release cytotoxic Pt(II) species and ligands.34,41
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Table 1 Comparative properties of bioactive platinum complexes11–15
Pt complexes Mechanism of action Advantages Disadvantages Ref.
Cisplatin-like Pt(II)
complexes
Hydrolysis, covalent DNA
binding
FDA approved, high cure rate Poor pharmacokinetics, dose-limiting
side eﬀects, restricted anticancer
spectrum, lack of selectivity, high
incidence of resistance
5 and 6
Pt(II) complexes
diﬀerent from
cisplatin
Covalent or non-covalent DNA
binding
Overcome cisplatin resistance Limited selectivity, inherent systemic
toxicity
16–19
Photosensitive
Pt(II) complexes
Excitation of triplet oxygen
(PDT)
Good photoselectivity,
overcome cisplatin resistance
Oxygen dependence, limited λex
wavelength range
20 and 21
Photoactive Pt(II)
complexes
Photoactivation to form
cytotoxic Pt(II) species (PACT)
Oxygen independence High dark cytotoxicity, low
photocytotoxic indices
45–53
Chemically
reductive Pt(IV)
complexes
Reduction by bio-reductants Easy modification, improved
selectivity and cellular accumulation
Poor stability before entering cells 30–32
Photoactive Pt(IV)
complexes
Photoreduction to release
cytotoxic Pt(II) species and
radicals (PACT)
Oxygen independence, good dark
stability, overcome cisplatin
resistance, spatial and temporal
selectivity, easy modification
Low photocytotoxic indices, short λex
wavelength range, limited light
penetration
62, 68, 77
and 81
Review Inorganic Chemistry Frontiers
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• Photosubstitution: Pt(II) complexes with photolabile ligand
(e.g. curcumin) undergo ligand dissociation followed by
solvent substitution.45–49
• Photocleavage of ligand: Photon absorption by the metal
centre can result in the cleavage of organic bonds, (e.g. C–N,
N–O) in photosensitive o-nitrobenzyl alcohol derivatives co-
ordinated to platinum.50,51
• Photoswitching: Pt(II) complexes bridged by a diarylethene
ligand change the configuration of the ligand upon irradiation
to alter the cytotoxic properties.52,53
Although PACT is often compared with PDT since they both
require light to activate relatively non-toxic drugs, these two
classes of treatments present many diﬀerences.4 Generally,
PACT agents decompose upon irradiation, while PDT agents
are photostable. Notably, the oxygen-independent mechanism
of action of PACT agents improves their eﬃciency in hypoxic
tumours and represents a major advantage of PACT over PDT.
However, the development of PACT is still in its infancy,
and the current performance of PACT complexes is not com-
petitive with PDT photosensitisers.4 Some photosensitisers in
clinical trials exhibit extremely high photocytotoxicity indices
(photo-cytotoxicity/dark-cytotoxicity, e.g. TLD-1433, up to
105),54 and some can be excited by near infrared (NIR)
irradiation (e.g. WST-09, 763 nm).55 In contrast, the highest
reported photocytotoxicity index of PACT agents is 1880,56 and
the longest excitation wavelengths reported for simple metal
complex-based PACT agents are in the red region, which limits
light penetration into tissue to a depth of ca. 5 mm.57–59 To
enter clinical trials, more eﬀort needs to be invested into the
preclinical development of new PACT complexes.
3. Development of photoactive Pt(IV)
complexes
In general, photoactive Pt(IV) complexes contain axial, non-
leaving, and leaving ligands. Axial ligands can be used to tune
the physical and chemical properties of the complexes without
altering the structure of the active pharmacophore that is ulti-
mately released.60 Non-leaving ligands do not significantly
alter the reduction potential of Pt(IV) complexes and can be
varied to change their properties without reducing the dark
stability.61 Leaving ligands play key roles in photoactive Pt(IV)
complexes. Two main classes of Pt(IV) complexes, namely
diiodo- and diazido-Pt(IV) complexes, have been investigated as
photoactive Pt(IV) anticancer prodrugs (Scheme 1).
Diiodo-Pt(IV)-ethylenediamines bearing various axial
ligands (Cl, OH, OCOCH3, OSO2CH3, or OCOCF3) were
reported by Kratochwil et al. in 1996 as the first-generation
photoactive Pt(IV) complexes with a general formula trans, cis-
[Pt(X)2I2(en)] (Fig. 1).
62–66 Iodide is a weak field ligand with a
low optical electronegativity,67 and thus the LMCT bands of
these complexes are centred at the relatively longer wavelength
of ca. 400 nm with a tail extending out into the visible range.62
As a result, all of these complexes are photolabile to light λirr >
375 nm. However, their application is limited due to their poor
dark stability, which might be due to facile cellular bio-
reduction. For example, electron donation to Pt(IV) can occur
through thiolate attack on iodide ligands.65
The second-generation photoactive Pt(IV) complexes with
azide ligands, were developed later to achieve better dark stabi-
lity and photobiological properties with a general formula
[Pt(N3)2(L)(L′)(OR)(OR′)] (Fig. 2, Table 2). The first diazido-
Pt(IV) complexes, cis, trans-[Pt(en)(N3)2(OH)2] (1) and cis, trans,
cis-[Pt(N3)2(OH)2(NH3)2] (2) were reported in 2003.
68
Cytotoxicity studies showed that these complexes caused very
low inhibition of growth in the dark, but significantly
enhanced cytotoxicity upon irradiation in both 5637 bladder
Scheme 1 Timeline illustrating the publication year for important photoactive Pt(IV) complexes.
Fig. 1 First-generation photoactive diiodo-Pt(IV) complexes.
Inorganic Chemistry Frontiers Review
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Fig. 2 Selected second-generation photoactive diazido-platinum(IV) complexes.
Table 2 LMCT bands and IC50 values for selected photoactive diazido-Pt(IV) complexes
Complex
Non-leaving ligands
LMCT band λmax nm
−1
(N3→ Pt) λirr/nm Cell line
IC50 values
a/μM
Ref.L1 L2 cis/trans Light Dark PI
[Pt(N3)2(CN)4]
2− CN CN t 302 302 — — — — 38
[Pt(N3)6]
2− — — 308 314 — — — — 39 and 40
1 en c 315 365 5637 63.0 ± 20.2 440 ± 143 7.0 68 and 69
365 5637-CDDP 79.8 ± 16.6 >200 >2.5
2 NH3 NH3 c 256 365 5637 49.3 ± 28.1 357 ± 81 7.2 68 and 69
365 HaCaT 169.3 >287.9 >1.7 74
3 NH3 NH3 t 285 365 HaCaT 121.2 >287.9 >2.4 70 and 74
4 NH3 MA t 286 365 HaCaT 65.6 >276.8 >4.2 74 and 76
5 NH3 Py c 258 365 HaCaT 100.9 >244.4 >2.4 74
6 NH3 Py t 289 365 HaCaT 6.8 >244.4 >35.9 74 and 77
7 NH3 c 259 365 HaCaT >236.2 >236.2 — 74
8 NH3 t 289 365 HaCaT 22.0 144.1 6.6 74 and 76
9 NH3 t 288 366 5637 29.17 ± 2.23 >80 >2.7 79
10 NH3 t 287 365 — — — — 75
11 Py MA t 289 365 HaCaT 2.6 >236.3 >90.8 80
420 HaCaT 14.7 >236.3 >16.0
12 Tz MA t 289 365 HaCaT 3.5 >232.9 >66.5 80
420 HaCaT 11.2 >232.9 >20.7
13 Py Py t 294 365 HaCaT 1.4 >212.3 >151.6 81
420 HaCaT 9.5 >212.3 >22.3
365 A2780 1.4 >212.3 >151.6
365 A2780cis 14.5 >212.3 >14.6
14 Bpy c 304/315 365 — — — — 83
15 Phen c 300 365 — — — — 83
aNote that IC50 values were obtained via diﬀerent methods/conditions. PI = Photocytotoxicity index.
Review Inorganic Chemistry Frontiers
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cells and cisplatin-resistant 5637 bladder cells, even though to
a less extent than cisplatin.69
Intriguingly, the all trans photoactive Pt(IV) prodrug, trans,
trans, trans-[Pt(N3)2(OH)2(NH3)2] (3), exhibited higher aqueous
solubility and a more intense and red-shifted LMCT band com-
pared with its cis isomer 2.70 Higher photocytotoxicity induced
by 3 upon irradiation (as toxic as cisplatin) was determined in
cancer cells, which was in contrast to the early structure–
activity relationship for classical anticancer platinum com-
plexes that the cis geometry was more favourable.71–73
Comparisons between other diazido Pt(IV) complexes incorpor-
ating a wide range of aliphatic and aromatic amines confirmed
the higher potency of the trans configuration.74,75
The introduction of a methyl substituent into an ammonia
ligand improved the photocytotoxicity of the Pt(IV) complexes
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(MA)] (4, MA = methyl-
amine).74,76 Furthermore, replacement of an ammine ligand in
3 by a π-acceptor pyridine (Py) ligand resulted in the highly
phototoxic complex trans, trans, trans-[Pt(N3)2(OH)2(NH3)(Py)]
(6) that showed 13–80× higher photocytotoxicity compared
with cisplatin, and 15× higher towards cisplatin-resistant
human ovarian A2780cis cells.77 Notably, 6 is the only simple
diazido-Pt(IV) prodrug that has been tested in vivo. Two of
seven nude mice bearing OE19 oesophageal cancer xenografts
treated with 6 at low dose with short irradiation times
(420 nm, 100 J cm−2, 2 × 30 min) survived at 35 days, while
none of the control mice without drug or irradiation survived,
and the complex was well tolerated.78 Encouraged by the
success of 6, a series of ligands was introduced to replace one
or both of the ammine ligands. The replacement of pyridine
by 3-methylpyridine (8),74,76 piperidine (9),79 or 4-nitro-pyri-
dine (10)75 did not result in significant diﬀerences. Higher
cytotoxicity of complexes with methylamine trans, trans, trans-
[Pt(N3)2(OH)2(MA)(Py)] (11) and trans, trans, trans-
[Pt(N3)2(OH)2(MA)(Tz)] (12, Tz = thiazole) was attributed to the
high stability of Pt–MA bonds.80 In addition, the Tz-containing
analogue 12 was more eﬀective towards the cisplatin resistant
cell lines.
The key role of pyridine ligands in the high phototoxicity
and the mechanism of action diﬀerent from cisplatin pro-
moted the development of a novel diazido-Pt(IV) complex with
two pyridine ligands, trans, trans, trans-[Pt(N3)2(OH)2(Py)2]
(13).81 Upon irradiation with UVA or visible blue light, 13
exhibited significant toxicity toward a number of human cell
lines with high phototoxicity indices. Dinuclear complexes
based on 13 also displayed photodecomposition with blue
light irradiation.82
Diazido-Pt(IV) complexes incorporating π-conjugated biden-
tate diimine ligands trans, cis-[Pt(2,2′-Bpy)(OAc)2(N3)2] (14, 2,2′-
Bpy = 2,2′-bipyridine) and trans, cis-[Pt(Phen)(OAc)2(N3)2] (15,
Phen = phenanthroline) exhibited greater absorption at longer
wavelengths compared with previously reported diazido-Pt(IV)
complexes.83 Their photodecompositions were observed upon
irradiation with both UVA and visible green light.
Other than iodide and azide, chloride is also a potential
candidate as leaving ligand for photoactive Pt(IV) complexes.
Upon irradiation, photoreduction to Pt(II) species was observed
for trans-[PtCl2(2,2′-Bpy)(MA)2]Cl2, mer-[PtCl3(2,2′-Bpy)(MA)]Cl,
[PtCl4(2,2′-Bpy)], and trans, trans, trans-[PtCl2(OH)2(DMA)(IPA)]
(Fig. 3, DMA = dimethylamine, IPA = isopropylamine).84–86
Some Pt(IV) complexes with chloride ligands, such as oxopla-
tin, even though not photoactive on their own, exhibit photo-
release of Pt(II) species when conjugated to specific
nanoparticles.87,88
4. Photochemistry and photobiology
of diazido Pt(IV) complexes
4.1. Photodecomposition pathways
Photodecomposition of diazido Pt(IV) complexes mainly relies
on the reduction of Pt(IV) and the release of azide ligands trig-
gered by light (Fig. 4a).38 The strong absorbance, assigned to a
dissociative LMCT band (N3 → Pt), is a key transition in
photodecomposition.70,74,75 Upon irradiation, a rapid decrease
in intensity of the LMCT band can be observed for diazido Pt
(IV) complexes due to the release of azide ligands (Fig. 4b and
c).38,41 The wavelength of the LMCT band is aﬀected signifi-
cantly by the overall configuration of Pt(IV).70,74,75,89 In general,
complexes with cis-{PtIV(N3)2} motifs exhibit LMCT bands at
shorter wavelength (ca. 260 nm), while those of trans isomers
are red-shifted by 30 nm (ca. 290 nm) (Table 2).74 However,
complexes with bidentate chelating non-leaving ligands
display LMCT bands at longer wavelength (ca. 300 nm) than
diazido Pt(IV) complexes with only monodentate ligands,
despite of their cis configuration.68,83,89 Electronic transitions
Fig. 3 Photoactive Pt(IV) complexes with chlorides as leaving ligands.
Fig. 4 (a) A possible mechanism for the photoreduction of diazido-
Pt(IV) complexes;91 UV-vis spectral changes for (b) 2 and (c) 3 in aqueous
solution upon UVA irradiation.70 Adapted from ref. 91 and 70.
Inorganic Chemistry Frontiers Review
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for cis isomers tend to arise from transitions from orbitals of
the azide ligands to metal d orbitals, whereas those for all-
trans isomers are more likely to arise from both axial and
azide ligands to the metal d orbitals, and thus lead to diﬀerent
photoproducts.75 The electron-donating and steric properties
of non-leaving ligands are also important factors which aﬀect
the LMCT band. The replacement of NH3 by a π-acceptor pyri-
dine ligand results in a red-shift of the intense LMCT band
(ca. 5 nm for each substitution).70,77,81 The substituents on pyr-
idine ligands aﬀect the maximum absorption slightly.75
The low-intensity transitions (the “tail”) that have mixed
dissociative 1LMCT/1IL (IL = interligand) character might
account for the photoactivity induced by longer wavelength
activation,75,81 which is a major challenge in the development
of new diazido Pt(IV) complexes. The low-intensity transitions
have significant contributions from the LUMO orbital that is
strongly σ-antibonding towards the two Pt–N3 bonds.81 Light
excitation to populate this orbital induces elongation of the
Pt–N3 bond, and eventually leads to azide release.
81 The weak
absorption of 13 in the blue region (414 nm) might be respon-
sible for its photodecomposition with visible light.81
Much eﬀort has been devoted to the investigation of the
photodecomposition pathways of the most promising diazido
Pt(IV) complexes. The early studies suggested that the photo-
decomposition involved the release of two azide ligands as N3
•
radicals, which can combine to form N2 molecules.
38 However,
during further investigation of diazido Pt(IV) complexes,
diﬀerent pathways have been proposed depending on the con-
figuration of Pt(IV), non-leaving ligands, and the solution
environment.
1D 14N{1H} NMR spectra of 15N-labelled 2 with two 15NH3
in acidic aqueous solution (pH = 5.1) upon irradiation with
UVA (365 nm) suggested the formation of N2 and unlabelled
free NH3, with a pH increased to 10.7 and O2 liberation
detected.90 In addition, the major Pt(II) species detected was
assigned to trans-[Pt(NH3)2(H2O)2]
2+, indicating photoisomeri-
sation with photoreduction. Nitrene intermediates generated
during the photodecomposition were trapped by dimethyl sul-
phide (DMS), which suggested a possible new mechanism.90
However, the photodecomposition of 2 in PBS involved the
photosubstitution of at least one azide ligand by H2O/OH and
the release of azide ions (Fig. 5).91 Ammonia ligands were also
released from Pt(IV) as confirmed by NMR with an increase in
pH. After replacement of both azides (or even ammonia
ligands) by H2O/OH, photoreduction may occur by one-elec-
tron transfers from each of two hydroxide groups coordinated
to the Pt(IV) leading to some species containing trans-{Pt(OH)2}
motifs and hydroxyl radicals. DFT and TD-DFT calculations
demonstrated the theoretical possibility of the replacement of
both NH3 and N3 groups trans to each other by H2O/OH.
92
The photodecomposition pathways for 3 in PBS and acidic
solution are similar to that of its cis isomer 2, in which the
azide ion was detected in PBS, while N2 was found in acidic
solution.93 Trans Pt(II) species, O2 and free ammonia were
detected as photoproducts of 3 with a subsequent increase in
pH in both basic and acidic solution. However, the trans
isomer 3 gave fewer types of Pt species in acidic solution, but
more minor side-products and less hydroxo-/oxo-bridged
species compared to its cis isomer 2.93 In addition, no photoi-
somerisation was observed in the photodecomposition of 3.
Even though azidyl radicals are regarded as important cyto-
toxic photoproducts of diazido Pt(IV) complexes, they were not
considered further in the early work.90–93 A recent study on the
first stage of photodecomposition using ultrafast kinetic spec-
troscopy and nanosecond laser flash photolysis suggested that
the photodecomposition of both cis 2 and trans 3 is a chain
process beginning with the replacement of one azide ligand by
a water molecule and the release of azidyl radicals.94 Two suc-
cessive Pt(III) intermediates participated in chain initiation
and [PtIII(NH3)2(OH)2]
+ was a chain carrier.
Fig. 5 Possible pathways for photodecomposition and photoreactions of complex 2 with 1-methylimidazole in PBS. Adapted from ref. 91.
Review Inorganic Chemistry Frontiers
Inorg. Chem. Front. This journal is © the Partner Organisations 2019
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 3
0 
M
ay
 2
01
9.
 D
ow
nl
oa
de
d 
on
 6
/2
5/
20
19
 4
:1
3:
39
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Trans-[Pt(OH)4(
15NH3)(Py)] and trans-[Pt(N3)(OH)3(
15NH3)
(Py)] were detected as photoproducts of 6 using 15NH3 and 1D
1H and 2D [1H, 15N] HSQC NMR spectroscopy, indicating the
release of azides.77 In contrast, no evidence of pyridine release
was found. Furthermore, very little reduction to Pt(II) species
was detected by NMR. Consistently, [Pt(OH)2NH3(Py)] and
[Pt(OH)(N3)(NH3)(Py)] at low concentration were detected by
LC-MS.95 In addition, [Pt(N3)3(OH)(NH3)(Py)] was observed by
LC-MS as a photosubstitution product of 6 as well as azide
ions, indicating the release of azide ligands.95 No platinum
species without pyridine were detected by LC-MS, in accord-
ance with NMR data. However, no detailed photo-
decomposition pathway has been proposed for 6 so far. For its
piperidine analogue 9, only [Pt(OH)2(piperidine)NH3] was
detected as a product by LC-MS, suggesting an eﬀect of the
heterocyclic ring on the photodecomposition pathways.96 The
MA analogue of 6, 11 produced N2, N3
−, N3 radicals and
1O2
upon irradiation, with Pt–nitrene intermediates involved in the
pathway (Fig. 6).97
Comprehensive spectroscopic studies of the photo-
decomposition of the most promising diazido Pt(IV) complex
13 have been performed by Attenuated Total Reflection Fourier
Transform Infrared (ATR-FTIR) and NMR.81,98 ATR-FTIR
revealed the binding of water to platinum in the final product,
which was assigned as trans-[PtII(Py)2(H2O/OH)2] fitted by
Multi-Curve Resolution Alternating Least Squares (MCR-ALS).
Trans-[PtII(N3)(Py)2(H2O/OH)] was detected as an intermediate,
implying release of at least one hydroxyl radical and one
azidyl radical or two hydroxyl radicals during the photoreduc-
tion.98 No pyridine release was detected by 1H NMR, in con-
trast to NH3 complexes, and might contribute to its higher
potency.81
4.2. Photoreactions with important biomolecules
The cytotoxicity of diazido Pt(IV) complexes is mediated by the
photoreduction products, including Pt(II) species, azidyl rad-
icals and ROS, and their interactions with biomolecules,
including nucleotides, DNA, amino acids, peptides and
proteins.35,41
The RNA monomer nucleotide guanosine monophosphate
(5′-GMP) is often used as a model for nucleobase guanine, con-
sidered to be the major target of Pt anticancer drugs on
DNA.99,100 Unlike Pt(II) complexes, diazido Pt(IV) complexes do
not interact with 5′-GMP in the dark, but only upon
irradiation, forming mono- and/or bis-GMP adducts. A bis-
GMP adduct [Pt(en)(GMP-N7)2]
2+ was detected by NMR when 1
reacted with two mol. equiv. of 5′-GMP upon irradiation with
visible light (457.9 nm), while [Pt(en){d(GpG)-N71,N72}]2+ was
the only major photoproduct of 1 in the presence of one mol.
equiv. of d(GpG).68 Similar results were found for 2 and 3.68,70
Interestingly, trans 3 was able to form a bis(5′-GMP) adduct
under UVA irradiation at a faster rate than transplatin.70 In
addition, the photodecomposition of 3 was accelerated in the
presence of 5′-GMP, and a few Pt-GMP adducts were even
detected upon red light irradiation.70 For 6, the Pt(II) mono-
GMP adduct [Pt(N3)(NH3)(5′-GMP)(Py)]
+ was detected as the
initial main photoproduct from reaction with 5′-GMP, while
the bis-5′-GMP adduct trans-[Pt(NH3)(Py)(5′-GMP)2]
2+ became
predominant at longer irradiation times.77 Unexpectedly,
guanine photooxidation by 11 was observed via a mechanism
involving 1O2, while the NH3 ligand in the adducts probably
arose from the formation of a Pt–nitrene intermediate
(Fig. 6).97 Both mono- and bis-GMP adducts (trans-[Pt(N3)
(Py)2(5′-GMP)]
+ and trans-[Pt(Py)2(5′-GMP)2]
2+) were detected as
photoproducts of 13 and 5′-GMP by NMR, LC-MS and
ATR-FTIR spectra.81,98
DNA platination photoinduced by 1 with rb = 0.01 (rb = Pt
coordinated per nucleotide residue) gave a preference for GG
sequences, forming bifunctional GG adducts, which is similar
to cisplatin.101 Intriguingly, photoactivated 1 and 2 formed GG
adducts more rapidly than cisplatin.69 Transcription mapping
revealed similar major stop sites in a DNA fragment treated
with 6 and irradiation or with transplatin, while the level of
DNA adducts formed by irradiated 6 was significantly higher
than that by cisplatin and transplatin.77 DNA interstrand
cross-links and DNA–protein cross-links were also induced by
6 with light. Remarkably, a plasmid treated with 6 and UVA
exhibited considerably lower levels of damage-induced DNA
Fig. 6 Possible pathways for photodecomposition and photoreactions of 11 with 5’-GMP upon irradiation with UVA. Adapted from ref. 97.
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repair synthesis than those with cisplatin. Significantly larger
unwinding angles and a higher percentage of interstrand
cross-links were observed when DNA was treated with 11 or
12 compared to cisplatin.80 The nature of DNA lesions
induced by 13 upon irradiation was expected to be diﬀerent
from those induced by cisplatin.81 Irreversible DNA coordi-
nation was observed for 13 with light, including ca. 12%
interstrand (intramolecular) cross-links, ca. 37% monofunc-
tional adducts, and ca. 51% intrastrand cross-links.102 The
interstrand cross-links formed by 13 and light were character-
ised, and the structure of a trans-{Pt(Py)2}
2+-DNA showing a
bend toward the minor groove, a global bend of ca. 67° and
an unwinding of ca. 20° was simulated by computational
studies (Fig. 7).103
Other than nucleotides and DNA, amino acid, peptides and
proteins are also targets for Pt(II) species released from diazido
Pt(IV) complexes. The photoactivated platinum centre of 2 can
also react with dimethyl sulphide, a thioether related to that in
the side chain of the amino acid methionine (Met), in acidic
solution. The nitrene intermediate formed dimethylsulfilimine
adducts that can undergo a Stevens-like rearrangement in
which the Pt–NvSMe2 group becomes Pt–N(H)–CH2–SMe,
giving a N-(methylthiomethylene)amido derivative.90 The
derivative can release two hydroxyl radicals upon irradiation.90
The photoreaction between 2 and 1-methylimidazole, a histi-
dine (His) side chain analogue, in PBS (Fig. 5) gave 6 diﬀerent
Pt-coordinated 1-methylimidazole species, suggesting it can
bind to proteins.91
Azidyl radicals are potentially key species, which might kill
cancer cells by oxidative attack. Azidyl radicals generated by 13
can be trapped by 5,5-dimethyl-1-pyrroline N-oxide (DMPO)
and detected using EPR (Fig. 8a).104 However, in the presence
of Trp, the azidyl radicals were quenched, which reduced the
photocytotoxicity of 13.104 The resulting tryptophan (Trp) rad-
icals have been trapped by 2-methyl-2-nitrosopropane (MNP)
and such radicals might be involved in the cytotoxicity towards
cancer cells (Fig. 8b).105 Background signals from di-tert-butyl
nitroxide (DTBN) radicals arose from MNP upon irradiation.
The Trp containing peptide pentagastrin also quenched azidyl
radicals (Fig. 8c), although not as eﬃciently as Trp.105 The
antioxidant melatonin (MLT) quenched azidyl radicals and
formed MLT radicals in a similar way to Trp.105 In contrast,
other amino acids, including Tyr (tyrosine) and His, were
unable to quench azidyl radicals despite of their important
roles in electron transfer.104,105
A combined attack on peptides by photoactivated 13,
involving sequence-dependent platination and radical
mechanisms, was observed using UHR-FT-ICR MS and
EPR.106 Two model peptides with amidated C-termini,
Substance P (SubP) and [Lys]3-Bombesin (K3-Bom), were
treated with 13 and irradiation. SubP gave rise to only mono-
platinated adducts with diﬀerent amino acids, while K3-Bom
showed both mono- and di-platinated adducts with a preference
for His. In contrast, oxidation of SubP occurred only at Met,
whereas oxidation of both Met and Trp was observed for K3-
Bom. Thioredoxin (Trx) is an important enzyme in the redox sig-
nalling pathway and is usually overexpressed in tumour cells.107
Platination of His, Glu (glutamic acid), and Gln (glutamine) resi-
dues of Trx and oxidation of Met, Trp, and the Cys catalytic sites
induced by 13 upon irradiation can inhibit the activity of
Trx enzyme and Trx system, and further increase the cellular
ROS level.108
4.3. Eﬀects on cancer cellular components and pathways
Photoreactions between photoactivated diazido Pt(IV) com-
plexes and important biomolecules can result in the dysfunc-
tion of cellular components, changes to cellular morphology
and disruption of cellular pathways, and eventually cell death.
The ability to damage DNA in intact cells has been investi-
gated for both cis 2 and trans 3 using comet assays.70 Both
complexes produced DNA cross-links in living cells upon
Fig. 7 (a) The average ligand ﬁeld molecular dynamics (LFMD) structure
of trans-{Pt(Py)2}
2+-DNA derived from simulations; (b) an expanded view of
the platinum-binding site showing the G7–G19 interstrand cross-link within
the DNA duplex dodecamer, d(5’-C1C2T3C4T5C6G7T8C9T10C11C12-3’)·d
(5’-G13G14A15G16A17C18G19A20G21A22G23G24-3’). Adapted from ref. 103.
Fig. 8 EPR spectra of 13 in PBS upon irradiation in the presence of spin-
traps (a) DMPO for N3
• radicals; (b) Trp + MNP for Trp• radicals (and back-
ground DTBN• radicals); (c) pentagastrin + DMPO for N3
• radicals (red:
with pentagastrin; black: without pentagastrin). Adapted from ref. 105.
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irradiation and the eﬀects were similar to those produced by
cisplatin. When 5637 bladder cells were treated with 2 in the
presence of light, dramatic changes in the morphology of the
cells occurred, including cellular shrinkage, loss of adhesion
with neighbouring cells, a large amount of nuclear packing,
and nuclei disintegration, suggesting a diﬀerent mechanism
of cell death compared to cisplatin (Fig. 9).69 None of these
eﬀects was observed without irradiation. Intriguingly, typical
hallmarks of apoptosis, budding and cellular fragmentation,
were not observed.
Single-cell electrophoresis experiments indicated that
diﬀerent DNA damage in HaCaT keratinocyte cells was caused
by 6 and light with limited inhibition of DNA migration com-
pared to cisplatin.77 Also, p53 protein did not accumulate in
cells, and caspase 3 activity was not detected when treated
with 6 and irradiation, which was diﬀerent from cells treated
with cisplatin.77 An autophagic mechanism was envisaged for
6 based on a significant increase in LC3B-II level and a
decreased p62 level in treated cells.78 Cell swelling and very
little blebbing was seen for HL60 cells treated with irradiated
6.78 Notably, light activation was found to enhance the cellular
accumulation of 6.79
Excellent nuclear DNA binding properties were observed for
photoactivated 13 that was shown to be a potent inhibitor to
stall RNA pol II for RNA synthesis.102 In contrast to cisplatin,
photoactivated 13 did not produce fragmented or condensed
nuclei, indicating a diﬀerent mechanism.81
5. Derivatisation of photoactive
diazido Pt(IV) complexes
The axial ligands (with arbitrary choice of OH as axial ligands)
of photoactive Pt(IV) complexes can not only be released,
similar to azide ligands, upon photoreduction to Pt(II), but
also greatly aﬀect the reduction potential of Pt(IV).66,75
Generally, Pt(IV) complexes with a lower reduction potential
(depending on the axial ligand: I− > Cl− > OAc− > OH−) exhibit
higher stability to reductants.60,66 Thus, the hydroxide ligands
can enhance aqueous solubility and also stabilise the Pt(IV) oxi-
dation state.109 Modification of axial ligands is a feasible
method to improve the selectivity and cytotoxicity of diazido-
Pt(IV) complexes.
5.1. Multi-action diazido-Pt(IV) complexes
By combining photoactive Pt(IV) complexes with other anti-
cancer active agents, such as stable radicals, enzyme inhibi-
tors, and photosensitisers, multi-action prodrugs are obtained.
Upon irradiation, these prodrugs release not only the reactive
Pt(II) species and azidyl radicals, but also additional cytotoxic
agents, enhancing the anticancer eﬃcacy of the drugs. Owing
to their diﬀerent cellular targets and mechanism of action,
combination of these cytotoxic species often results in a syner-
gistic eﬀect, producing greater cytotoxicity than that expected
by simple addition of the two agents. Examples of diazido-
Pt(IV) multi-action agents are summarised below.
Dinuclear complexes such as 16, in which two molecules of
13 are bridged in an axial position by bisamide dicarboxylato
linkers (Fig. 10) display similar photocytotoxicity towards cis-
platin-resistant ovarian A2780cis and A2780 cells, and interest-
ingly are relatively non-toxic toward normal cells (MRC-5 lung
fibroblasts).82
The TEMPO radical has been conjugated to 13 since nitrox-
ide radicals themselves can possess potent anticancer activity
(17, Fig. 10).110 The presence of the TEMPO radical in the
complex was confirmed by EPR spectroscopy. Upon irradiation
with blue light (420 nm), azidyl and TEMPO radicals were
released, accompanied by the formation of toxic Pt(II) species.
Suberoyl-bis-hydroxamic acid (SubH) is a histone deacety-
lase (HDAC) inhibitor, which exhibits a profound dose-depen-
dent inhibition of cancer cell proliferation.111 Two SubH
ligands have been attached to the axial positions of cis, trans-
[Pt(N3)2(OH)2(tBu2bpy)] to generate a diazido-Pt(IV) complex,
cis, trans-[Pt(N3)2(Sub)2(tBu2bpy)] (18, Fig. 10), that was stable
Fig. 9 Fluorescence microscopy images of 5637 cells treated by 2 with
and without irradiation. Adapted from ref. 69.
Fig. 10 Multi-action diazido-Pt(IV) complexes 16–18.
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in the dark.112 Complex 18 released SubH and cytotoxic Pt(II)
species, which targeted similar DNA regions as cisplatin
eﬃciently upon UVA irradiation. Photoactivated 18 exhibited
significant cytotoxicity in cancer cells with a low resistance
factor compared with cisplatin and its Pt(IV) analogues con-
taining inactive axial ligands. This suggested a diﬀerent
mechanism of action involving inhibition of HDAC that
allowed platinum species to access chromatin DNA, introduced
eﬀective steric blockage of RNA polymerase II and formed
DNA adducts (e.g. interstrand cross-links).
Metal complexes with curcumin ligands exhibit photo-
induced anticancer activity.113 Light activation of curcumin-
loaded Dex-2 nanoparticles 19 led to instant production of
ROS by curcumin and released Pt(II) species from 2 (Fig. 11),
and gave rise to photocytotoxicity and in vivo antitumour
eﬃcacy with low systemic toxicity to KM mice bearing sub-
cutaneous H22 murine hepatocarcinoma tumour.114
The amphiphilic oligomer Ce6-PEG-Pt(IV) (CPP, 20, Fig. 12)
can self-assemble into micelles, and upconversion nano-
particles (UCNP) NaYbF4: Tm@CaF2 have been co-assembled
to convert NIR into shorter wavelength irradiation that can
induce decomposition of diazido-Pt(IV) complexes.115 Micelles
as self-assembled nanoparticles with a hydrophilic corona and
hydrophobic core have been widely used in anticancer drug
delivery.116 Attachment of the photosensitiser Chlorin e6 to
complex 2 resulted in an O2-self generating PACT-PDT agent,
where the photosensitiser relied on the oxygen produced by
photoactivation of the diazido-Pt(IV) fragment to supply the
oxygen required for PDT in hypoxic tissues. Dramatically
enhanced photocytotoxicity was observed for this PACT-PDT
system in hypoxic tumour models.
The nanoparticle-based agent 21 has complex 13 loaded
onto silica-coated UCNP to allow photoactivation with NIR,
together with a fluorescent probe that can be selectively
switched-on in apoptotic conditions (Fig. 13a).117 The probe
included a fluorescence resonance energy transfer (FRET) pair,
consisting of a far-red fluorescence donor Cy5 and a NIR
quencher Qsy21, linked by a peptide sequence that can be
recognised and cleaved by caspase-3, a key enzyme in apopto-
sis. Accordingly, when 21 was photoactivated by NIR
irradiation, a chain reaction in A2780 ovarian cancer cells
started on triggering apoptosis, thus activating caspase-3,
which in turn cleaved the peptide-linker, switching on emis-
sion of the Cy5 dye and enabling imaging of apoptosis in
living cells. Notably, when both peptide probe and Pt(IV)
complex 13 were conjugated to human serum albumin protein
(HSA, 22, Fig. 13b), instead of UCNP, improved photocytotoxi-
city and real-time imaging was also achieved upon UVA
irradiation.118
The nano-system 23, combining Yb/Tm-codoped UCNP and
6, exhibited better tumour inhibition under NIR irradiation
than that under UV irradiation (Fig. 14).119 Notably, this nano-
system functioned as a theragnostic agent, whose therapeutic
action could be informed and guided by diﬀerent imaging
modalities, such as upconversion luminescence (UCL), mag-
netic resonance (MR) and computer tomography (CT).
5.2. Targeted delivery of diazido-Pt(IV) complexes
One of the major advantages of phototherapy over traditional
chemotherapy is the ability to provide spatial and temporal
control of the activation of prodrugs and their resulting cyto-
toxic activity. However, ineﬃcient accumulation of photoactive
prodrugs at the tumour site is still an issue and results in the
Fig. 11 Preparation and photodecomposition of curcumin-loaded Dex-
2 nanoparticles 19. Adapted from ref. 114.
Fig. 12 The amphiphilic oligomer 20 and the photodecomposition of
UCPP in a tumour microenvironment. Adapted from ref. 115.
Fig. 13 Photoactivation of conjugates 21 and 22 based on (a) UNCP117
and (b) HSA,118 respectively. Adapted from ref. 117 and 118.
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need for higher concentrations to achieve therapeutic eﬃcacy,
increasing the risk of side eﬀects. The conjugation of diazido
Pt(IV) complexes with cancer-targeting vectors can improve
their selectivity, increase their accumulation in cancer cells,
and enable the prodrugs to be activated specifically within
cancer cells.
Overexpression of particular receptors on the surface of
cancer cells provides an excellent strategy for the targeted
delivery of diazido-Pt(IV) complexes by tethering them to
ligands that can bind selectively to those receptors. The RGD
sequence (–Arg–Gly–Asp–) can be selectively recognised by αvβ3
and αvβ5 integrins that are overexpressed on the surface of
several tumour cells and related to tumour angiogenesis.120,121
The conjugate of photoactive Pt(IV) prodrug 13 and a cyclic
RGD-containing peptide c(RGDfK) (24, Fig. 15) showed
remarkably enhanced selectivity and increased cellular
accumulation for cells overexpressing αvβ3 and αvβ5 integrins,
although the IC50 values for irradiated cells were higher than
those of its parent succinylated complex.122 Another example
of targeting for complex 13 is its conjugate with guanidinoneo-
mycin, which is a RNA-binding ligand and allows the complex
to be taken up by cancer cells in a selective proteoglycan-
dependent manner (25, Fig. 15).123 The photoproducts of
Pt–guanidinoneomycin conjugate 25 with 5′-GMP or
5′-dCATGGCT were similar to that of the parent complexes
under the same conditions. Similar to the Pt–c(RGDfK) conju-
gate, the Pt–guanidinoneomycin conjugate exhibited an
enhanced cellular uptake with a preference for the
SK-MEL-28 malignant melanoma cell line due to the
expression of negatively charged cell-surface proteoglycans.
Nanoparticle-based drug delivery systems have attracted
particular attention due to their enhanced accumulation in
tumour tissue through the enhanced permeation and reten-
tion (EPR) eﬀect caused by the leaky nature of angiogenic
blood vessels in solid tumours.88,124,125 The PtIV-N3-FA@CDs
nanoplatform 26 (Fig. 15) consisted of carbon dots decorated
with the photoactive diazido Pt(IV) prodrug cis, trans, cis-
[Pt(N3)2(OH)2(NH3)(3-NH2-Py)] and folic acid (FA) molecules,
and exhibited a preference for folate receptor FR-positive
[FR(+)] human cervical HeLa cells over FR-negative [FR(−)]
MCF-7 human breast tumour cells.126
Photo-responsive block copolymer (BCP) micelles have been
widely investigated for their drug delivery applications in
cancer therapy.127 The triblock copolymer methoxy-poly
(ethylene glycol)-block-poly(ε-caprolactone)-block-poly-L-lysine,
mPEG114-b-PCL20-b-PLL10 that included mPEG (n = 114), poly-
caprolactone (p = 20) and poly-L-lysine (q = 10) self-assembles
in aqueous solution, with polycaprolactone and poly-L-lysine
forming the core with Pt(IV) complex cis, trans-
[Pt(1R,2R-DACH)(N3)2(OH)2] (DACH = 1,2-cyclohexanediamine)
covalently encapsulated inside the hydrophobic core via an
amide linkage (27, Fig. 16).128 The micelles exhibit greatly
enhanced cellular accumulation and photocytotoxicity to
Fig. 14 Schematic illustration of the photodecomposition of conjugate
23. Adapted from ref. 119.
Fig. 15 Diazido-Pt(IV) complexes 24–26 with cancer cell-targeting
vectors. CDs = carbon dots.
Fig. 16 The preparation and photodecomposition of micelles 27,128
28,129 29 130 assembled by mPEG114-b-PCL20-b-PLL10 polymer with
diazido Pt(IV) complexes. Adapted from ref. 129.
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SKOV-3 ovarian cancer cells compared with polymer-free pro-
drugs. Importantly, in vivo studies revealed that conjugation to
micelles enhanced the blood circulation half-life of the Pt(IV)
complex by 10-fold and displayed improved inhibition
eﬃcacy against H22 murine hepatocarcinoma with decreased
systemic toxicity. Complex 3 was also attached to the bio-
degradable polymer mPEG114-b-PCL20-b-PLL10 that can self-
assemble into micelles with the hydrophobic chain and Pt
species as the core to protect Pt(IV) prodrugs from potential de-
activation in blood circulation.129 The micelles 28 (Fig. 16) dis-
played comparable IC50 values to cisplatin upon irradiation
and a resistance factor (IC50 ratio: A2780CDDP/A2780) 5× lower
than cisplatin. When the same micelles incorporated sterically
hindered 6, they were proved to be >100 times more eﬀective
than cisplatin upon UVA irradiation (29, Fig. 16).130
The photocleavable tri-block copolymers PEG-PUPt(N3)-PEG
(PUPt(N3) is polyurethane with repeating 13 bricks) produced a
photosensitive micelle 30 (Fig. 17).131 The in vivo experiments
revealed that the irradiated micelle (430 nm) was 3–4× more
eﬀective to BALB/c nude mice bearing A549 xenografts than
the prodrug and cisplatin with lowest body weight loss on day
27, suggesting lower systemic toxicity.
Complex 2-loaded amphiphiles with one lactose motif self-
assembled into micelles 31, while the amphiphiles with two
lactose motifs formed vesicles 32 instead (Fig. 18). These nano-
particles displayed photocytotoxicity with liver cancer-targeting
ability in vivo. The platinum distribution in mice was deter-
mined by fluorescence, CT and ICP-MS.132
For surface tumours, such as non-melanoma skin cancer,
topical medication is an ideal way for precise localisation.
G4K
+ hydrogels are biocompatible polymers with flexibility and
high water content that allow them to mimic natural
tissues.133–135 Pt(IV)-based Pt-G4K
+ B hydrogel 33 (Fig. 19)
exhibited potent photocytotoxicity towards cisplatin-resistant
A2780cis ovarian cancer cells while it displayed negligible cyto-
toxicity to MRC-5 normal fibroblast cells.136
6. Conclusions and prospects for
clinical platinum photochemotherapy
Photoactive diazido-Pt(IV) complexes represent a new gene-
ration of platinum anticancer prodrugs that allow spatial and
temporal control over their cytotoxic activity. They exhibit high
dark stability, promising oxygen-independent photocytotoxi-
city, and novel mechanisms of action that allow them to cir-
cumvent cisplatin resistance. Modification of the prototype
complexes (1–15), especially the axial ligands, improves their
targeting ability and pharmacological properties. In this
review, we have described the development of photoactive
diazido-Pt(IV) complexes, including their cancer-targeting
derivatives, and discussed their photodecomposition path-
ways, photoreaction with biomolecules, and their eﬀect on cel-
lular components and pathways.
Three main features of an ideal diazido-Pt(IV) complex for
PACT appear to be crucial and need to be considered in any
further development of these agents. (1) In contrast to cispla-
tin, trans geometry is more favourable than cis for diazido-
Pt(IV) complexes, owing to the more intense and red-shifted
LMCT bands, faster photodecomposition rate and improved
photocytotoxicity. (2) The replacement of NH3 by a π-acceptor
pyridine ligand can not only red-shift the LMCT bands, but
also enhance the cytotoxicity and introduce new mechanisms
of action. Also, replacement of NH3 by an aliphatic amine (e.g.
CH3NH2) improves photocytotoxicity. (3) Axial derivatisation of
Fig. 17 The preparation and photodecomposition of micelles 30
assembled by a tri-block copolymer with complex 13. Adapted from ref.
131.
Fig. 18 Cancer-targeting micelles 31 and vesicles 32. Adapted from ref.
132.
Fig. 19 Schematic illustration of self-assembled Pt-G4K
+B anticancer
hydrogel 33. Adapted from ref. 136.
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hydroxide/carboxylate ligands with cancer-targeting vectors or
cytotoxic motifs provides an avenue for the design of new
diazido-Pt(IV) complexes with improved selectivity, cellular
accumulation and photocytotoxicity, longer activation wave-
length, and convenient formulation.
In spite of the notable progress with research development
of photoactive diazido-Pt(IV) complexes achieved so far, none
of them has yet entered clinical trials. The achievement of
longer wavelength activation for deeper tissue penetration,
higher photocytoxicity indices, and tumour specific drug deliv-
ery remain major challenges to be further addressed. However,
there are good prospects for use of such complexes for surface
cancers such as bladder and oesophageal cancer. Hence there
are encouraging signs that diazido-Pt(IV) complexes can
provide novel PACT anticancer drugs with new mechanisms of
action which can be eﬀective against resistant cancers, so war-
ranting further investigation.
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